Meta-analysis of observational studies: Hepatitis C and survival after renal transplant

Journal of Viral Hepatitis

Volumn 21, Issue 5, 2014, Pages 314-324

  Fabrizi, F ^a   Martin, P ^b   Dixit, V ^b   Messa, P ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

graft loss; Hepatitis C renal transplant; liver disease; survival

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; INTERLEUKIN 2 RECEPTOR;

ARTICLE; CAUSE OF DEATH; CLINICAL STUDY; DIABETES MELLITUS; END STAGE RENAL DISEASE; FOLLOW UP; GRAFT DYSFUNCTION; GRAFT FAILURE; GRAFT SURVIVAL; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY GRAFT; LIVER FIBROSIS; LIVING DONOR; META ANALYSIS; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR; SYSTEMATIC REVIEW; ADULT; AGED; FEMALE; GRAFT RECIPIENT; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; SURVIVAL; YOUNG ADULT;

ADULT; AGED; FEMALE; GRAFT SURVIVAL; HEPATITIS C; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TRANSPLANT RECIPIENTS; YOUNG ADULT;

EID: 84898420176     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12148     Document Type: Article

References (39)

1. Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of Hepatitis C in chronic kidney disease. Kidney Int 2008; 73 (Suppl. 109): S1-S99
2. Pol S, Debure A, Degott C, et al,. Chronic hepatitis in kidney allograft recipients. Lancet 1990; 335: 878-880.
3. Seeff L,. The history of the 'natural history' of hepatitis C (1968-2009). Liver Int 2009; 29: 89-99.
4. Fabrizi F, Lunghi G, Colucci P, Finazzi S, Ponticelli C, Locatelli F,. Reduced aminotransferase activity in patients with chronic renal failure not requiring dialysis: impact on the evaluation of viral hepatitis. Am J Kidney Dis 2001; 28: 1009-1015.
5. Hanuka N, Sikuler E, Tovbin D, et al,. Hepatitis C virus infection in renal failure patients in the absence of anti-hepatitis C virus antibodies. J Viral Hepat 2002; 9: 141-145.
6. Morales J, Bloom R, Roth D,. Kidney transplantation in the patient with hepatitis C virus infection. Contrib Nephrol 2012; 176: 10-23.
7. Roth D, Gaynor J, Reddy K, et al,. Effect of kidney transplantation on outcomes among patients with hepatitis C. J Am Soc Nephrol 2011; 22: 1152-1160.
8. DerSimonian R, Laird N,. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
9. Takkouche B, Cadarso-Suarez C, Spiegelman D,. Evaluation of old and new tests for heterogeneity in epidemiologic meta-analysis. Am J Epidemiol 1999; 150: 206-211.
10. Kelley G, Kelley K,. Statistical methods for meta-analysis: a brief tutorial. World J Methodol 2012; 2: 27-32.
11. Costa-Bouzas J, Takkouche B, Cadarso-Suarez C, Spiegelman D,. HEpiMA: software for the identification of heterogeneity in meta-analysis. Comp Meth Progr Biomed 2001; 64: 101-107.
12. Borenstein M, Higgins J,. Meta-analysis and subgroups. Prevention Sci 2013; 14: 134-143.
13. Pereira B, Wright T, Schmid C, Levey AS,. The impact of pre-transplantation hepatitis C infection on the outcome of renal transplantation. Transplantation 1995; 60: 799-805.
14. Pereira B, Wright T, Schmid C, Levey A, for The New England Organ Bank Hepatitis C Study Group. A controlled study of hepatitis C transmission by organ transplantation. Lancet 1995; 345: 484-487.
15. Bouthot B, Murthy B, Schmid C, Levey A, Pereira B,. Long-term follow-up of hepatitis C virus infection among organ transplant recipients. Transplantation 1997; 63: 849-853.
16. Legendre C, Garrigue V, Le Bihan C, et al,. Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients. Transplantation 1998; 65: 667-670.
17. Batty D, Swanson S, Kirk A, Ko C, Agodoa L, Abbott K,. Hepatitis C virus sero-positivity at the time of renal transplantation in the United States: associated factors and patient survival. Am J Transplant 2001; 1: 179-184.
18. Breitenfeldt M, Rasenack J, Berthold H, et al,. Impact of hepatitis B and C on graft loss and mortality of patients after kidney transplantation. Clin Transplant 2002; 16: 130-136.
19. Forman J, Tolkoff-Rubin N, Pascual M, Lin J,. Hepatitis C, acute humoral rejection, and renal allograft survival. Kidney Int 2004; 15: 3249-3255.
20. Bruchfeld A, Wilczek H, Elinder C,. Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantation. Transplantation 2004; 78: 745-750.
21. Mahmoud I, Elhabashi A, Elsawy E, El-Husseini A, Sheha G, Sobh M,. The impact of hepatitis C virus viraemia on renal graft and patient survival: a 9-year prospective study. Am J Kidney Dis 2004; 43: 131-139.
22. Aroldi A, Lampertico P, Montagnino G, et al,. Natural history of hepatitis B and C in renal allograft recipients. Transplantation 2005; 79: 1132-1136.
23. Mitwalli A, Alam A, Al-Wakeel J, et al,. Effect of chronic viral hepatitis on graft survival in Saudi renal transplant patients. Nephron Clin Pract 2006; 102: c72-c80.
24. Einollahi B, Pourfarziani V, Ahmadzad-Asl M, et al,. Iranian model of renal allograft transplantation in 3028 recipients: survival and risk factors. Transplant Proc 2007; 39: 907-910.
25. Ingsathit A, Thakkinstian A, Kantachuvesiri S, Sumethkul V,. Different impacts of hepatitis B virus and hepatitis C virus on the outcome of kidney transplantation. Transplant Proc 2007; 39: 1424-1428.
26. Luan F, Schaubel D, Zhang H, et al,. Impact of immunosuppressive regimen on survival of kidney transplant recipients with hepatitis C. Transplantation 2008; 85: 1601-1606.
27. Gentil M, Rodriguez-Benot A, Sola E, et al,. Trends in kidney transplantation outcome: the Andalusian Kidney Transplant Registry, 1984-2007. Transplant Proc 2009; 41: 1583-1585.
28. Ridruejo E, Diaz C, Michel M, et al,. Short and long term outcome of kidney transplanted patients with chronic viral hepatitis B and C. Ann Hepatol 2010; 9: 271-277.
29. Morales J, Marcen R, Andres A, et al,. Renal transplantation in patients with hepatitis C virus antibody. A long national experience. NDT Plus 2010; 3 (Suppl. 2): ii41-ii46.
30. Scott D, Wong J, Spicer T, et al,. Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand. Transplantation 2010; 90: 1165-1171.
31. Singh N, Neidlinger N, Djamali A, et al,. The impact of hepatitis C virus donor and recipient status on long-term kidney transplant outcomes: University of Wisconsin experience. Clin Transplant 2012; 26: 684-693.
32. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G,. Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant 2005; 5: 1452-1461.
33. Kamar N, Rostaing L, Selves J, et al,. Natural history of hepatitis C virus-related liver fibrosis after renal transplantation. Am J Transplant 2005; 5: 1704-1712.
34. Zylberberg H, Nalpas VB, Carnot F, et al,. Severe evolution of chronic hepatitis C in renal transplantation: a case control study. Nephrol Dial Transplant 2002; 17: 129-133.
35. Lopez-Medrano F, Fernandez-Ruiz M, Morales J, et al,., and the RESITRA/REIPI Study Group. Impact of hepatitis C virus infection on the risk of infectious complications after kidney transplantation: data from the RESITRA/REIPI Cohort. Transplantation 2011; 92: 543-549.
36. Fabrizi F, Messa P, Martin P, Takkouche B,. Hepatitis C virus infection and post-transplant diabetes mellitus among renal transplant patients: A meta-analysis. Int J Artif Organs 2008; 31: 675-682.
37. Cruzado J, Bestard O, Grinyo J,. Impact of extra-hepatic complications (diabetes and glomerulonephritis) associated with hepatitis C virus infection after renal transplantation. Contrib Nephrol 2012; 176: 108-116.
38. Baid-Agrawal S, Farris A, Pascual M, et al,. Overlapping pathways to transplant glomerulopathy: chronic humoral rejection, hepatitis C infection, and thrombotic microangiopathy. Kidney Int 2011; 80: 879-885.
39. Khan K, Daya S, Jadad AR,. The importance of quality of primary studies in producing unbiased systematic reviews. Arch Int Med 1996; 156: 661-666.